These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 3860185

  • 1. Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.
    Sullam PM, Täuber MG, Hackbarth CJ, Chambers HF, Scott KG, Sande MA.
    Antimicrob Agents Chemother; 1985 May; 27(5):685-7. PubMed ID: 3860185
    [Abstract] [Full Text] [Related]

  • 2. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.
    Chambers HF, Sande MA.
    Antimicrob Agents Chemother; 1984 Jul; 26(1):61-4. PubMed ID: 6236747
    [Abstract] [Full Text] [Related]

  • 3. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro.
    Chambers HF, Hackbarth CJ, Drake TA, Rusnak MG, Sande MA.
    J Infect Dis; 1984 Jun; 149(6):894-903. PubMed ID: 6564133
    [Abstract] [Full Text] [Related]

  • 4. Correlates of therapeutic efficacy in experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Bayer AS, Greenberg DP, Yih J.
    Chemotherapy; 1988 Jun; 34(1):46-55. PubMed ID: 3162413
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
    Thauvin C, Lemeland JF, Humbert G, Fillastre JP.
    Antimicrob Agents Chemother; 1988 Jun; 32(6):919-21. PubMed ID: 3166360
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.
    Fernandez-Guerrero M, Rouse M, Henry N, Wilson W.
    Antimicrob Agents Chemother; 1988 May; 32(5):747-51. PubMed ID: 3164989
    [Abstract] [Full Text] [Related]

  • 8. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW, Barriere SL, Schaberg DR, Fekety R.
    Antimicrob Agents Chemother; 1987 Apr; 31(4):527-30. PubMed ID: 3649202
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.
    Carpenter TC, Hackbarth CJ, Chambers HF, Sande MA.
    Antimicrob Agents Chemother; 1986 Sep; 30(3):382-4. PubMed ID: 3640590
    [Abstract] [Full Text] [Related]

  • 10. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Gilbert M, Boscia JA, Kobasa WD, Kaye D.
    Antimicrob Agents Chemother; 1986 Mar; 29(3):461-3. PubMed ID: 3459391
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG, Basuino L, Chambers HF.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [Abstract] [Full Text] [Related]

  • 12. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.
    Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ.
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1547-50. PubMed ID: 1929325
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ.
    Antimicrob Agents Chemother; 1989 Apr; 33(4):519-21. PubMed ID: 2499251
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Imipenem therapy of experimental Staphylococcus epidermidis endocarditis.
    Berry AJ, Johnston JL, Archer GL.
    Antimicrob Agents Chemother; 1986 May; 29(5):748-52. PubMed ID: 3460523
    [Abstract] [Full Text] [Related]

  • 17. [Comparative in vitro antistaphylococcal effect of norfloxacin and pefloxacin on 312 hospital strains].
    Ronco E, Pilliot J.
    Pathol Biol (Paris); 1985 May; 33(5):381-4. PubMed ID: 3162139
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
    Kaatz GW, Seo SM, Lamp KC, Bailey EM, Rybak MJ.
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1192-7. PubMed ID: 1329613
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations.
    Bayer AS, Lam K.
    J Infect Dis; 1985 Jan; 151(1):157-65. PubMed ID: 3965588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.